Alteplase
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
- Alteplase
- Pharmacist Assessment Report
- Alteplase: recombinant tissue plasminogen activator → heparin cofactor 2 deficiency
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Alteplase: recombinant tissue plasminogen activator → heparin cofactor 2 deficiency
One-Sentence Summary
Alteplase is a recombinant tissue plasminogen activator, a clot-dissolving (thrombolytic) drug that is currently marketed in Canada. The TxGNN model predicts it may be useful for heparin cofactor 2 deficiency, an inherited clotting disorder. This prediction rests on the model score alone: there are no clinical trials and no publications directly studying this disease.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | heparin cofactor 2 deficiency |
| TxGNN Prediction Score | 0.9972 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 3) |
| Number of DINs | 3 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for alteplase are not available in the data compiled for this report. Alteplase is generally understood to act by converting plasminogen to plasmin, which breaks down fibrin in blood clots.
Heparin cofactor 2 deficiency is an inherited thrombophilia, meaning a tendency to form abnormal clots. In principle, an acute clot in an affected patient could be dissolved by a fibrinolytic drug such as alteplase. That is the only reasoning offered for this prediction, and it comes from the model score rather than from any study.
Alteplase would not correct the underlying deficiency. It could at most treat a clot that has already formed. This is a plausible but unverified idea, and the model’s high score should not be read as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered for heparin cofactor 2 deficiency.
Literature Evidence
Currently no related literature available for heparin cofactor 2 deficiency.
Canada Market Information
Alteplase has three valid authorizations in Canada. The local data do not record dosage form or approved indication text for them.
| DIN | Product Name |
|---|---|
| 02245859 | CATHFLO |
| 02225689 | ACTIVASE RT-PA |
| 02147440 | ACTIVASE RT-PA |
Safety Considerations
Package insert warnings and contraindications are not available in the compiled data. Please refer to the package insert for them.
Drug Interactions: The interaction screen recorded 100 interacting drugs. The first 20 returned include the following.
- Major: deferasirox, ibritumomab tiuxetan, tositumomab (including I-131 tositumomab), abciximab, acalabrutinib, fondaparinux, anisindione and apixaban. Most of these affect bleeding or clotting, so combined use needs close attention to bleeding risk.
- Moderate: acetylsalicylic acid, ibuprofen, ketorolac (including ophthalmic), fluvoxamine, fosinopril, aminocaproic acid, aprotinin, dexfenfluramine, fenfluramine and sibutramine.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials or publications for this disease, so the evidence level is L5. Alteplase also would not treat the underlying deficiency.
To proceed, the following is needed:
- Clinical or case evidence that directly addresses heparin cofactor 2 deficiency
- Mechanism-of-action data for alteplase
- Package insert warnings and contraindications from Health Canada
- A bleeding-risk and concurrent-anticoagulation plan for patients with inherited clotting disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.